LABSTYLE INNOVATIONS TO PRESENT AT THE 12th ANNUAL NEEDHAM HEALTHCARE CONFERENCE
Apr 22, 2013
RAMAT GAN, Israel (April 22, 2013) – LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ smartphone-based diabetes management system, today announced that Dr. Oren Fuerst, LabStyle’s Chairman and Chief Executive Officer, will present at the 12th Annual Needham Healthcare Conference on Tuesday, April 30 at 4:20 p.m., Eastern Time. The presentation will provide a corporate overview and a discussion of LabStyle’s growth strategy.
The conference will be held at The Westin Grand Central Hotel, 212 East 42nd Street, in New York City from April 30 to May 1, 2013.
Dr. Fuerst’s presentation will be webcast. To listen to and view the presentation, interested parties may visit the investor relations section of LabStyle’s website at www.mydario.com or at the following link: http://wsw.com/webcast/needham58/drio/. In addition, the presentation and audio will be archived on the Company’s website for 30 days.
About LabStyle Innovations
LabStyle Innovations Corp. has developed and is commercializing a patent-pending technology that seeks to bring laboratory testing capabilities to consumers in a distinctive, easy to use and affordable way through the use of smartphones such as iPhones. LabStyle’s initial product is Dario™, a stylish, easy-to-use device and software system that will compete in the multibillion-dollar market for patient self-monitoring of blood glucose (SMBG) products. Dario is a comprehensive, patent-pending system that combines an all-in-one SMBG device consisting of a lancet (to obtain a blood sample), a device-specific disposable test strip cartridge and a smartphone-driven glucose reader adaptor, coupled with a smartphone app and internet-based data services.
Cautionary Note Regarding Forward-Looking Statements
This news release, the presentation referred to herein, and the statements of representatives of LabStyle Innovations Corp. (the “Company”) related thereto contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “plan,” “project,” “seek,” "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for regulatory approvals for, and the commercial launch of, Dario) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
Kim Sutton Golodetz
Bruce Voss, 310-691-7100
LabStyle Innovations Corp.
Oren Fuerst, Chairman/CEO